. 2022 Sep 26;11(10):e220322. doi: 10.1530/EC-22-0322
This work is licensed under a Table 2.
Characteristics of trials included in dose–response meta-analysis of alpha-lipoic acid supplementation in patients with type 2 diabetes.
| Reference, country | Participants (n) | Age (mean ± s.d. or range) | Study design (duration, week) | Diabetes duration (years) | Intervention (dose) | Control |
|---|---|---|---|---|---|---|
| Didangelos, 2020, Greece (35) | Type 2 diabetes mellitus patients with diabetes duration and metformin treatment for at least 4 years and HbA1C between 6.5 and 7.5% (85) | >50 | Parallel (52) | 15 | ALA (570) | Placebo |
| Baziar, 2020, Iran (36) | Non-insulin-dependent diabetes mellitus patients with a BMI between 18.5 and 29.9 kg/m2, aged between 40 and 60 years old, diagnosis of type 2 diabetes mellitus for at least two years, and HbA1c < 7% (70) | 40–60 | Parallel (8) | 3.6 | ALA (1200 mg/day) | Placebo |
| Mendoza-Núñez, 2019, Mexico (37) | Type 2 diabetes mellitus patients with a body mass indexBMI between <35 kg/m2, mean age of 64 ± 1 years, diagnosis of type 2 diabetes mellitus for at least 2 years, and HbA1C < 7% (135) | 64 ± 1 | Parallel (26) | 1–3 | ALA (600 mg/day) | Placebo |
| Lee, 2017, Korea (38) | Type 2 diabetes patients between 20 and 80 years, with HbA1c < 11% (75) | >50 | Parallel (12) | 12.6 | ALA (600 mg/day) | Placebo |
| Derosa, 2016, Italy (39) | 18–75 years of age, with type 2 diabetes, HbA1c > 7%, and BMI ≥ 25 and < 30 kg/m2 (105) | 18–75 | Parallel (12) | Not reported (NR) | ALA (600 mg/day) | Placebo |
| Al-Saber, 2016, Bahrain (40) | Type 2 diabetes mellitus with HbA1c ≥ 6.5 and ≤ 10%, between 20 and 75 years old, BMI ≤ 44 kg/m2 (53) | >40 | Parallel (12) | NR | ALA (200 mg/day) | Placebo |
| Okanović, 2015, Bosnia and Herzegovina (15) | Obese patients with type 2 diabetes mellitus, BMI between 18.50 and 24.99 kg/m2, concentration of glucose between 4.4 and 6.1 mmol/L (60) | ≥60 | Parallel (20) | NR | ALA (600 mg/day) | Placebo |
| Udupa, 2013, India (41) | Type 2 diabetes mellitus patients between 21 and 65 years, with fasting blood sugar between 110 and 250 mg/dL (50) | 21–65 | Parallel (12) | NR | ALA (300 mg/day) | Placebo |
| Porasuphatana, 2012, Thailand (42) | Type 2 diabetes mellitus patients. Inclusion criteria included glycemic status and microalbuminuria (20–200 mg/dL) (38) | 44 ± 0.88 | Parallel (26) | 2.1 | ALA (600 mg/day) | Placebo |
| Koh, 2011, Korea (43) | Type 2 diabetes mellitus obese subjects aged 18–65 years with a BMI ≥ 30 kg/m2, fasting plasma glucose concentration ≥ 126 mg/dL (98) | >35 | Parallel (20) | NR | ALA (1200 mg/day) | Placebo |
| de Oliveira, 2011, Brazil (44) | Type 2 diabetes mellitus patients ranging in age from 38 to 75 years, at least 2 years since the diagnosis of diabetes, HbA1C > 7%, (52) | Parallel (16) | NR | ALA (600 mg/day) | Placebo | |
| Ansar, 2011, Iran (45) | Type 2 diabetes mellitus adults with a mean age of 53 years, diabetes’ duration > 1 year, and a fasting blood glucose > 126 mg/dL (57) | 53 | Parallel (8) | 7 | ALA (300 mg/day) | Placebo |
| Lukaszuk, 2009, USA (46) | Type 2 diabetics, 21–65 years, nonpregnant or lactating (20) | 21–65 | Parallel (12) | ≥1 | ALA (600 mg/day) | Placebo |
| Gianturco, 2009, Italy (47) | Type 2 diabetes mellitus patients, >50 years, diabetes diagnosis at least 5 years, HbA1C < 7% (14) | >50 | Parallel (4) | 5 | ALA (400 mg/day) | Placebo |
| Chang, 2007, Korea (48) | Hemodialysis type 2 diabetes patients, mean age of 64 years (50) | >55 | Parallel (12) | NR | ALA (600 mg/day) | Placebo |
| Ziegler, 1997, Germany (49) | Type 2 diabetes mellitus patients, aged >18 and ≤70 years, (73) | >55 | Parallel (16) | 15.2 | ALA (800 mg/day) | Placebo |